相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infection
Sheryl A. Zelenitsky et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Evaluation of different tests based on observations for external model evaluation of population analyses
Karl Brendel et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Probability of Pharmacodynamic Target Attainment With Standard and Prolonged-Infusion Antibiotic Regimens for Empiric Therapy in Adults With Hospital-Acquired Pneumonia
Aryun Kim et al.
CLINICAL THERAPEUTICS (2009)
In Vitro Activity and Pharmacodynamics of Commonly Used Antibiotics Against Adult Systemic Isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals
Kathryn J. Eagye et al.
CLINICAL THERAPEUTICS (2009)
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C-glabrata in a neutropenic murine candidiasis model
D. R. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models:: The npde add-on package for R
Emmanuelle Comets et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2008)
Antibiotic resistance - What's dosing got to do with it?
Jason A. Roberts et al.
CRITICAL CARE MEDICINE (2008)
Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches
Jean-Marie Conil et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2008)
Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
Christopher R. Frei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study
Arthur R. H. van Zanten et al.
JOURNAL OF CRITICAL CARE (2008)
Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonide in Brooklyn, NY
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Simulated comparison of the pharmacodynamics of ciprofloxacin and Levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data
David S. Burgess et al.
CLINICAL THERAPEUTICS (2007)
Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa
Frederique Pasquali et al.
VETERINARY MICROBIOLOGY (2007)
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
Karl Brendel et al.
PHARMACEUTICAL RESEARCH (2006)
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa
GT Hansen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations
S Zelenitsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacodynamics of antimicrobials for the empirical treatment of nosocmial pneumonia: A report from the OPTAMA Program
HK Sun et al.
CRITICAL CARE MEDICINE (2005)
Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli
LL Marcusson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
JW Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Impact of restricting fluoroquinolone prescription on bacterial, resistance in an intensive care unit
G Aubert et al.
JOURNAL OF HOSPITAL INFECTION (2005)
Antimicrobial therapy in critically ill patients - A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability
F Pea et al.
CLINICAL PHARMACOKINETICS (2005)
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe
RG Masterton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy
DE Croisier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions
HJ Linde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia:: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants
D Croisier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in north America in 2002
JL Kuti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination
AA Firsov et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program:: the OPTAMA Program, South America 2002
CRV Kiffer et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window:: related changes in susceptibility, resistance frequency and bacterial killing
SH Zinner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Treatment and outcome of Pseudomonas aeruginosa bacteraemia:: an antibiotic pharmacodynamic analysis
SA Zelenitsky et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
The mutant selection window and antimicrobial resistance
K Drlica
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus
AA Firsov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
2003 report by the members of the French Society of Microbiology Antiobiogram Committee
G Carret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Antibiotic resistance among gram-negative bacilli in US intensive care units - Implications for fluoroquinolone use
MM Neuhauser et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Prevention of resistance: A goal for dose selection for antimicrobial agents
GL Drusano
CLINICAL INFECTIOUS DISEASES (2003)
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa
DS Burgess et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2002)
Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models
A MacGowan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Clinical role of protein binding of quinolones
E Bergogne-Berezin
CLINICAL PHARMACOKINETICS (2002)
Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies
XL Zhao et al.
CLINICAL INFECTIOUS DISEASES (2001)
Pharmacokinetic aspects of treating infections in the intensive care unit - Focus on drug interactions
F Pea et al.
CLINICAL PHARMACOKINETICS (2001)
Mutant prevention concentration as a measure of antibiotic potency:: Studies with clinical isolates of Mycobacterium tuberculosis
YZ Dong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
